Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Cytokinetics Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2022 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial performance, as measured by economic value added (EVA) metrics, demonstrates a consistently negative economic profit over the five-year period. Net operating profit after taxes (NOPAT) remained negative throughout, contributing to the overall negative economic profit. Invested capital fluctuated significantly, moving from negative values to a positive value in 2021 before returning to a negative value in 2022. The cost of capital exhibited relative stability, decreasing slightly over the period.

NOPAT Trend
Net operating profit after taxes consistently remained negative, worsening significantly from 2018 to 2022. The magnitude of the loss increased substantially, moving from approximately $106 million in 2018 to $460 million in 2022. This indicates a sustained inability to generate operating profits sufficient to cover tax obligations.
Cost of Capital Trend
The cost of capital decreased modestly from 15.32% in 2018 to 14.38% in 2022. While a decrease in the cost of capital is generally favorable, it did not offset the negative impact of consistently negative NOPAT.
Invested Capital Trend
Invested capital displayed considerable volatility. It began as a negative value, became positive in 2021, and then reverted to a negative value in 2022. The shift to a positive value in 2021 suggests a temporary increase in assets financed by debt or equity, while the subsequent return to a negative value indicates a potential reduction in net invested assets or a change in financing structure. The large negative value in 2022 is particularly noteworthy.
Economic Profit Trend
Economic profit was negative in each year examined, and the magnitude of the loss increased over time. The economic profit moved from approximately $94 million in 2018 to $443 million in 2022. This indicates that the company’s returns on invested capital were consistently below its cost of capital, resulting in value destruction. The substantial increase in the loss from 2021 to 2022 is a significant concern.

In summary, the observed trends suggest a continuing pattern of value destruction. The consistently negative NOPAT, coupled with a cost of capital that, while decreasing, remained substantial, resulted in increasingly negative economic profit. The volatility in invested capital further complicates the financial picture.


Net Operating Profit after Taxes (NOPAT)

Cytokinetics Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss
Deferred income tax expense (benefit)1
Increase (decrease) in deferred revenue2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in deferred revenue.

3 Addition of increase (decrease) in equity equivalents to net loss.

4 2022 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2022 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net loss.

7 2022 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


Net Loss Trend
The net loss demonstrates a consistent and significant increase over the five-year period. Beginning at approximately -106.3 million US dollars at the end of 2018, the net loss gradually worsened to -121.7 million in 2019 and further to -127.3 million in 2020. A sharper escalation is observed in 2021, with the net loss reaching approximately -215.3 million US dollars, followed by a substantial further decline to -389.0 million US dollars in 2022. This indicates increasing expenses, reduced revenues, or other factors contributing to growing financial challenges over time.
Net Operating Profit After Taxes (NOPAT) Trend
NOPAT follows a somewhat different trajectory from net loss but remains negative throughout the observed period. It starts at around -105.9 million US dollars in 2018 and deteriorates slightly to -119.5 million in 2019. In 2020, there is a notable improvement, with NOPAT improving substantially to approximately -31.6 million US dollars, indicating either a reduction in operating losses or improved operational efficiency during that year. However, this improvement is not sustained, as NOPAT declines sharply in 2021 to around -193.1 million, and further worsens to an estimated -460.0 million US dollars by the end of 2022. This sharp downturn in recent years suggests significant operational challenges impacting profitability after taxes.
Overall Financial Performance Insights
The increasing net losses alongside the fluctuating but largely negative NOPAT values suggest persistent financial difficulties with a notable deterioration in both net loss and operating profitability in the last two years of the data. The brief improvement in NOPAT in 2020 could reflect transient operational efficiencies or cost management, which were not maintained amid subsequent increases in losses. This pattern may warrant a deeper investigation into the underlying causes such as increased expenses, investments, or operational disruptions in the 2021 and 2022 periods.

Cash Operating Taxes

Cytokinetics Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Income tax provision
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The data presents a clear upward trend in cash operating taxes for the company over the observed period from December 31, 2018, to December 31, 2022. Starting at 102 thousand US dollars in 2018, the cash operating taxes increased significantly each year, peaking at 5,911 thousand US dollars by the end of 2021. However, in 2022, there was a noticeable decline to 4,236 thousand US dollars, indicating a reduction of approximately 28% from the previous year.

The absence of values for the income tax provision across all periods indicates either that such data was not reported or that there were no income tax provisions recognized during these years.

Overall, the cash operating taxes show a consistent upward trajectory with the exception of the last year, where a decline suggests possible changes in tax policy, operational conditions, or other factors impacting the tax liability related to cash operations. The lack of income tax provision data limits the ability to analyze comprehensive tax expense trends.


Invested Capital

Cytokinetics Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Current portion of term loan
Short-term finance lease liabilities
Term loan, net, excluding current portion
Convertible notes, net
Long-term finance lease liabilities
Operating lease liability1
Total reported debt & leases
Stockholders’ equity (deficit)
Net deferred tax (assets) liabilities2
Deferred revenue3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity (deficit)
Construction in progress6
Available-for-sale investments7
Invested capital

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of deferred revenue.

4 Addition of equity equivalents to stockholders’ equity (deficit).

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of available-for-sale investments.


Total reported debt & leases
The total reported debt and leases show a consistent and significant upward trend over the five-year period. Beginning at $52.8 million in 2018, the figure rose sharply to $136.1 million in 2019 and remained relatively stable in 2020. From 2020 onwards, the debt level surged substantially, reaching $271.2 million in 2021 and further increasing to $751.3 million by the end of 2022. This dramatic rise in debt indicates a growing reliance on external financing or obligations over time.
Stockholders’ equity (deficit)
Stockholders’ equity exhibits considerable volatility throughout the period. Initially, it was positive at $25.9 million in 2018. However, it turned negative in 2019, reflecting a deficit of approximately $10.9 million. The position improved markedly in 2020 and 2021, reaching a peak value of $243.9 million in 2021, indicating a strong equity base during these years. Nevertheless, by the end of 2022, stockholders’ equity declined sharply into a deficit of $107.9 million, suggesting a deterioration in the company’s net asset position in the most recent year.
Invested capital
Invested capital remained negative for the majority of the analyzed period, starting at a deficit of $78.3 million in 2018 and worsening slightly to $106.9 million in 2019. There was a modest improvement in 2020, yet the figure remained negative. A notable positive shift occurred in 2021, with invested capital rising to a positive $91.7 million, implying effective investment and capital utilization during that year. This positive trend was reversed in 2022, with invested capital declining sharply back into negative territory at $117.4 million, reflecting a significant decrease in net capital invested in the company.

Cost of Capital

Cytokinetics Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Cytokinetics Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2022 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial performance, as indicated by economic profit and invested capital, demonstrates significant fluctuations over the observed period. Economic profit consistently reflects negative values, suggesting the company has not generated returns exceeding its cost of capital during these years. Invested capital also exhibits variability, transitioning from negative values to a positive value in 2021 before returning to a negative value in 2022.

Economic Profit
Economic profit shows a worsening trend from 2018 to 2019, with losses increasing from US$93.918 million to US$103.407 million. A substantial improvement is noted in 2020, with the loss decreasing to US$19.294 million. However, this improvement is short-lived, as economic profit declines sharply in 2021 to a loss of US$206.808 million and further deteriorates in 2022, reaching a loss of US$443.133 million. This indicates increasing difficulty in generating returns above the cost of capital, particularly in the latter two years.
Invested Capital
Invested capital begins with negative values in 2018 and 2019, at US$78.273 million and US$106.877 million respectively. It remains negative in 2020, at US$87.987 million, but experiences a dramatic shift to a positive value of US$91.721 million in 2021. This positive value is not sustained, as invested capital returns to a negative value of US$117.411 million in 2022. The volatility in invested capital suggests significant changes in the company’s capital structure or asset base.
Economic Spread Ratio
The economic spread ratio is only available for 2021, registering at -225.48%. This substantial negative value indicates that the company’s return on invested capital was significantly lower than its cost of capital in that year. The absence of this ratio for other years limits the ability to assess trends in the relationship between returns and costs across the entire period.

The combined trends suggest a period of increasing financial strain, particularly in 2021 and 2022. While 2020 showed some improvement in economic profit, this was not sustained. The fluctuation in invested capital, coupled with consistently negative economic profit, raises concerns about the company’s ability to generate adequate returns and effectively utilize its capital.


Economic Profit Margin

Cytokinetics Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
 
Revenues
Add: Increase (decrease) in deferred revenue
Adjusted revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 2022 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The economic profit margin demonstrates significant volatility over the observed period. Initially, the company exhibited substantial negative economic profit margins, which improved considerably in 2020 before deteriorating sharply in subsequent years.

Economic Profit Margin Trend
In 2018 and 2019, the economic profit margin was markedly negative, registering at -298.14% and -384.87% respectively. This indicates a considerable shortfall in generating returns exceeding the cost of capital. A substantial improvement occurred in 2020, with the margin increasing to -13.51%, suggesting a reduction in the gap between economic profit and capital costs. However, this positive trend was reversed in 2021 and 2022. The economic profit margin declined to -293.64% in 2021 and plummeted to -5,839.92% in 2022.

The fluctuations in economic profit margin correlate with changes in adjusted revenues and economic profit. The substantial decline in 2022 is particularly noteworthy, coinciding with a significant reduction in adjusted revenues and a dramatic increase in the magnitude of the negative economic profit. This suggests a substantial erosion of value creation during that period.

Relationship to Adjusted Revenues
Adjusted revenues decreased from US$31.501 million in 2018 to US$7.588 million in 2022. The most significant decrease occurred between 2020 and 2022. The economic profit margin’s deterioration in 2021 and especially 2022 appears directly linked to this revenue decline, as the negative economic profit increased substantially while revenues contracted.

The consistently negative economic profit throughout the period indicates that the company has not generated returns sufficient to cover its cost of capital. The increasing magnitude of the negative economic profit, particularly in 2022, raises concerns about the company’s ability to create economic value.

Economic Profit
Economic profit itself was consistently negative throughout the period, ranging from -US$93.918 million to -US$443.133 million. The largest negative economic profit was recorded in 2022, aligning with the lowest adjusted revenues and the most negative economic profit margin.